"With Field Specialist Services, we take individualized training and coaching services to the territory, so sales representatives stay close to the business," said Marianne Nugent, vice president, Innovex Training Solutions. Innovex is a commercialization unit of Quintiles Transnational Corp. (Nasdaq: QTRN). "Keeping sales representatives in the field for training and instruction means representatives can maintain contact with their customers."

The staff of Field Specialist Services includes senior-level sales professionals with broad experience in field management and a wide range of therapeutic areas. Innovex Training Solutions works with customer sales operations to identify ways to streamline or expand functions as needed to meet customers' immediate and longer-term objectives.

The Field Specialists also provide individualized coaching services to guide sales representatives in shaping and achieving their professional goals. "Our aim is to help the individual sales representative achieve his or her personal best," Nugent said. "As individuals enhance their performance, the organization at large may experience higher productivity and greater retention of staff."

Innovex Field Specialist Services maintains a staff that is available to provide services throughout the United States. The group targets its services to new and emerging small and medium-sized companies.

Celltech Pharmaceuticals, Inc., the U.S. subsidiary of Celltech Group plc, recently used Innovex's Field Specialist Services to help support the launch of Metadate® CD Capsules, for the treatment of attention deficit hyperactivity disorder (ADHD) in patients six years of age and older.

"Celltech approached Innovex with specific conceptual sales training needs to supplement our in-house training programs and to take advantage of Innovex's experienced field managers," said Stuart Arbuckle, senior vice president, Sales and Marketing, Celltech Pharmaceuticals. "Together, Celltech and Innovex worked to create and deliver this unique service to fit specific requirements during the launch of our new ADHD product, Metadate® CD."

About Innovex

Innovex, a unit of Quintiles, is the world's leading commercial solutions provider and offers sales and marketing services designed to accelerate the success of pharmaceutical, biotech and medical device products. Since 1996, Innovex has created more than 94 contract sales forces in the United States, with more than 12,500 representatives who have launched more than 100 established products and 37 new products. For more information, visit www.innovex.com.

Quintiles Transnational Corp. is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve health care. Headquartered near Research Triangle Park, North Carolina, Quintiles Transnational is a member of the S&P 500 and Fortune 1000. For more information visit the company's Web site at www.quintiles.com.

Celltech Group plc (NYSE: CLL; LSE: CCH) is one of Europe's largest biopharmaceutical companies, with an extensive late stage development pipeline and a profitable cash-generative pharmaceutical business. Celltech also possesses drug discovery capabilities of exceptional strength, including a leading position in antibody engineering.

Information in this press release contains "forward looking statements" regarding Quintiles and Innovex that involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the risk that the market for our products and services will not grow as we expect, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.